Stage IIIC Cutaneous Melanoma AJCC v7 Completed Phase 3 Trials for Sargramostim (DB00020)

IndicationStatusPhase
DBCOND0091049 (Stage IIIC Cutaneous Melanoma AJCC v7)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01989572Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By SurgeryPrevention